Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: greedsgd_2000 who wrote (1770)	9/29/2000 7:16:05 PM
From: JMarcus	Respond to of 52153

Speaking of charts from BIOTECH HELL, check out SAFS, which has fallen to $1.75 from a 52-week high of $21. Since announcing on Sept. 21 that it had completed enrollment in its Phase II clinical trial of its lead drug candidate, GBC-590, to determine safety and efficacy in patients with refractory or relapsing colorectal carcinoma, the stock fell from $3+ to its current level. My guess it that the stock is being punished for poor sales in its non-drug business lines and that the potential value of its drug pipeline is not being reflected in the current stock price. If anyone has better information about why the stock price has descended into the nether regions, please enlighten me. Marc